Body Awareness, Upper Extremity Function, and Quality of Life in Breast Cancer Survivors

NCT ID: NCT07133087

Last Updated: 2025-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-06

Study Completion Date

2025-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer is one of the most common types of cancer among women and one of the leading causes of morbidity and mortality. With increasing survival rates, issues such as treatment-related morbidities and consequently upper extremity dysfunction, reduced body awareness, and decreased quality of life are frequently encountered. In the literature, the impact of treatment-related morbidities-particularly on upper extremity functions, body awareness, and quality of life-among women who have survived breast cancer treatment has not been sufficiently investigated. This gap constitutes a significant shortcoming in terms of clinical practices and the post-treatment period.

This study aims to examine the effects of breast cancer treatment on upper extremity functions, body awareness, and quality of life in women who have survived breast cancer treatment, in comparison with a healthy control group. The study will be conducted at Yeditepe University Koşuyolu Hospital between May, 2025, and October, 2025. Participants will include women who have survived breast cancer treatment and a healthy control group matched based on criteria such as age and body mass index.

In the study, three separate assessments will be conducted for upper extremity functions: the "Quick Disabilities of the Arm, Shoulder, and Hand" (QuickDASH) questionnaire for upper extremity functionality, a hand dynamometer for grip strength, and the Clinometer device for shoulder joint position sense. The "Body Awareness Questionnaire" will be used to assess body awareness, and the "EORTC QLQ-C30" scale will be used for quality of life assessment. The IBM SPSS Statistics software package will be used for data analysis. In statistical analyses, a significance level of p\<0.05 will be considered.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control group

A group of healthy subjects, matched with the breast cancer group based on criteria such as age and body mass index, will be included in the study.

No interventions assigned to this group

Breast cancer group

Women who have survived Stage 0-III breast cancer will be included in the study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Being a woman
* Being between the ages of 25 and 75
* Having been diagnosed with Stage 0-III breast cancer
* Having completed primary treatments (surgery, chemotherapy, and/or radiation therapy) no more than 6 months prior to the assessment date
* Having received medical clearance from a physician
* Having undergone either breast-conserving surgery or mastectomy due to breast cancer
* Willingness to participate in the study voluntarily


* Being a woman
* Having a body mass index (BMI) within ±3 kg/m² of the breast cancer survivor group
* Being within ±5 years of age compared to the breast cancer survivor group
* Matching hand dominance with the breast cancer survivor group

Exclusion Criteria

* Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within 6 months prior to the breast cancer diagnosis
* Having a history of neuromuscular dysfunction
* Using medications that may affect neuromuscular performance


* Having a history of neuromuscular dysfunction
* Using medications that may affect neuromuscular performance
* Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within the last 6 months
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Halic University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seda Saka, PhD

Role: STUDY_DIRECTOR

Haliç University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Halic University

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Yeditepe Hospital

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Seda Saka, PhD

Role: CONTACT

05447803417

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Seda Saka, phd

Role: primary

00905447803417

Dilek Şahinoğlu

Role: backup

DİLEK ŞAHİNOĞLU, PhD

Role: primary

05059594487

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ssaka10

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.